CERRITOS, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), a pioneer in value-based community oncology care, is proud to announce an enterprise-wide expansion of its strategic partnership with Helios Clinical Research, a nationally recognized research site network. This initiative builds upon a successful collaboration in Florida and reflects TOI’s ongoing commitment to integrating clinical research into community oncology settings.
“Expanding our research collaboration with Helios Clinical is a natural next step,” said Daniel Virnich, MD, CEO at TOI. “They’ve proven to be a highly capable partner, helping us streamline study activation, accelerate enrollment, and reduce operational burden on our sites. This move allows us to scale our research infrastructure much more quickly while staying laser-focused on patient care.”
Strategic Benefits of the Partnership:
“This isn’t just about geographic growth,” said Yale Podnos, MD, Chief Medical Officer at TOI. “It’s about ensuring that clinical research becomes a routine, integral part of patient care in every market we serve.”
About The Oncology Institute
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better. For more information, visit www.theoncologyinstitute.com
About Helios Clinical Research
Helios Clinical Research is a full-service site network known for its integrated, tech-forward approach to clinical trial execution. With expertise in oncology and a national footprint, Helios partners with leading healthcare organizations to bring high-performing, patient-first research capabilities into real-world care settings.
Contacts
Media
The Oncology Institute, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors
Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.15 |
Daily Change: | 0.28 9.69 |
Daily Volume: | 2,650,609 |
Market Cap: | US$289.330M |
June 30, 2025 May 14, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load